The prognostic significance of neuroendocrine differentiation in colorectal carcinomas: Our experience

Pooja Kundapur Suresh, Kausalya Kumari Sahu, Radha Ramachandra Pai, Hanaganahalli Basaviah Sridevi, Kirthinath Ballal, Binit Khandelia, Jessica Minal, Rajendra Annappa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Neuroendocrine differentiation in colorectal carcinomas, detected using immunohistochemistry and ultrastructural techniques, has been studied as a prognostic marker for invention of targeted therapy. There are a few studies done on this aspect which have shown conflicting results ranging from poor prognosis to no prognostic significance. Aim: The aim of the study was to determine the clinical significance of neuroendocrine differentiation in colorectal carcinomas using immunohistochemical stains such as chromogranin A & synaptophysin in relation to its prognostic significance. Materials and Methods: A retrospective study was conducted wherein all the colorectal carcinomas, received in the Department of Pathology, over a period of 3 years, were reviewed. Neuroendocrine markers were done on 53 cases of moderately, poorly and undifferentiated adenocarcinomas. Based on the degree of immunoreactivity for these markers, tumours were divided into group 0, group 1, group 2, group 3 & group 4. Group 0 & 1 were categorized as neuroendocrine differentiation absent & group 2, 3 & 4 as present. Neuroendocrine differentiation was correlated with age, sex, grade, stage, diagnosis & survival. Follow up data of the cases was recorded. Results: Neuroendocrine differentiation was present in 18 cases (33.9%). The degree of immunoreactivity for neuroendocrine markers in present study were; group 0- 58%, 1- 7.5%, 2- 9%, 3- 13% & 4- 11%. The mean age of patients was 54 years with a slight male preponderance {M:F::1.6:1}. Most of the carcinomas with neuroendocrine differentiation belonged to Grade II (61%) & Stage II & III (83%). Neuroendocrine differentiation did not show any significant association with age, sex, location, histological type, grade, stage & survival. Conclusion: The above results indicate that the presence of neuroendocrine differentiation cannot be recommended as a prognostic marker in colorectal carcinomas.

Original languageEnglish
Pages (from-to)EC01-EC04
JournalJournal of Clinical and Diagnostic Research
Volume9
Issue number12
DOIs
Publication statusPublished - 01-12-2015

Fingerprint

Chromogranin A
Synaptophysin
Patents and inventions
Pathology
Tumor Biomarkers
Colorectal Neoplasms
Coloring Agents
Neuroendocrine Carcinoma
Survival
Adenocarcinoma
Retrospective Studies
Immunohistochemistry
Therapeutics

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

@article{afb0d7fa223c4c9a8cb72c24244aaed7,
title = "The prognostic significance of neuroendocrine differentiation in colorectal carcinomas: Our experience",
abstract = "Introduction: Neuroendocrine differentiation in colorectal carcinomas, detected using immunohistochemistry and ultrastructural techniques, has been studied as a prognostic marker for invention of targeted therapy. There are a few studies done on this aspect which have shown conflicting results ranging from poor prognosis to no prognostic significance. Aim: The aim of the study was to determine the clinical significance of neuroendocrine differentiation in colorectal carcinomas using immunohistochemical stains such as chromogranin A & synaptophysin in relation to its prognostic significance. Materials and Methods: A retrospective study was conducted wherein all the colorectal carcinomas, received in the Department of Pathology, over a period of 3 years, were reviewed. Neuroendocrine markers were done on 53 cases of moderately, poorly and undifferentiated adenocarcinomas. Based on the degree of immunoreactivity for these markers, tumours were divided into group 0, group 1, group 2, group 3 & group 4. Group 0 & 1 were categorized as neuroendocrine differentiation absent & group 2, 3 & 4 as present. Neuroendocrine differentiation was correlated with age, sex, grade, stage, diagnosis & survival. Follow up data of the cases was recorded. Results: Neuroendocrine differentiation was present in 18 cases (33.9{\%}). The degree of immunoreactivity for neuroendocrine markers in present study were; group 0- 58{\%}, 1- 7.5{\%}, 2- 9{\%}, 3- 13{\%} & 4- 11{\%}. The mean age of patients was 54 years with a slight male preponderance {M:F::1.6:1}. Most of the carcinomas with neuroendocrine differentiation belonged to Grade II (61{\%}) & Stage II & III (83{\%}). Neuroendocrine differentiation did not show any significant association with age, sex, location, histological type, grade, stage & survival. Conclusion: The above results indicate that the presence of neuroendocrine differentiation cannot be recommended as a prognostic marker in colorectal carcinomas.",
author = "Suresh, {Pooja Kundapur} and Sahu, {Kausalya Kumari} and Pai, {Radha Ramachandra} and Sridevi, {Hanaganahalli Basaviah} and Kirthinath Ballal and Binit Khandelia and Jessica Minal and Rajendra Annappa",
year = "2015",
month = "12",
day = "1",
doi = "10.7860/JCDR/2015/12800.6854",
language = "English",
volume = "9",
pages = "EC01--EC04",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "12",

}

The prognostic significance of neuroendocrine differentiation in colorectal carcinomas : Our experience. / Suresh, Pooja Kundapur; Sahu, Kausalya Kumari; Pai, Radha Ramachandra; Sridevi, Hanaganahalli Basaviah; Ballal, Kirthinath; Khandelia, Binit; Minal, Jessica; Annappa, Rajendra.

In: Journal of Clinical and Diagnostic Research, Vol. 9, No. 12, 01.12.2015, p. EC01-EC04.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The prognostic significance of neuroendocrine differentiation in colorectal carcinomas

T2 - Our experience

AU - Suresh, Pooja Kundapur

AU - Sahu, Kausalya Kumari

AU - Pai, Radha Ramachandra

AU - Sridevi, Hanaganahalli Basaviah

AU - Ballal, Kirthinath

AU - Khandelia, Binit

AU - Minal, Jessica

AU - Annappa, Rajendra

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Introduction: Neuroendocrine differentiation in colorectal carcinomas, detected using immunohistochemistry and ultrastructural techniques, has been studied as a prognostic marker for invention of targeted therapy. There are a few studies done on this aspect which have shown conflicting results ranging from poor prognosis to no prognostic significance. Aim: The aim of the study was to determine the clinical significance of neuroendocrine differentiation in colorectal carcinomas using immunohistochemical stains such as chromogranin A & synaptophysin in relation to its prognostic significance. Materials and Methods: A retrospective study was conducted wherein all the colorectal carcinomas, received in the Department of Pathology, over a period of 3 years, were reviewed. Neuroendocrine markers were done on 53 cases of moderately, poorly and undifferentiated adenocarcinomas. Based on the degree of immunoreactivity for these markers, tumours were divided into group 0, group 1, group 2, group 3 & group 4. Group 0 & 1 were categorized as neuroendocrine differentiation absent & group 2, 3 & 4 as present. Neuroendocrine differentiation was correlated with age, sex, grade, stage, diagnosis & survival. Follow up data of the cases was recorded. Results: Neuroendocrine differentiation was present in 18 cases (33.9%). The degree of immunoreactivity for neuroendocrine markers in present study were; group 0- 58%, 1- 7.5%, 2- 9%, 3- 13% & 4- 11%. The mean age of patients was 54 years with a slight male preponderance {M:F::1.6:1}. Most of the carcinomas with neuroendocrine differentiation belonged to Grade II (61%) & Stage II & III (83%). Neuroendocrine differentiation did not show any significant association with age, sex, location, histological type, grade, stage & survival. Conclusion: The above results indicate that the presence of neuroendocrine differentiation cannot be recommended as a prognostic marker in colorectal carcinomas.

AB - Introduction: Neuroendocrine differentiation in colorectal carcinomas, detected using immunohistochemistry and ultrastructural techniques, has been studied as a prognostic marker for invention of targeted therapy. There are a few studies done on this aspect which have shown conflicting results ranging from poor prognosis to no prognostic significance. Aim: The aim of the study was to determine the clinical significance of neuroendocrine differentiation in colorectal carcinomas using immunohistochemical stains such as chromogranin A & synaptophysin in relation to its prognostic significance. Materials and Methods: A retrospective study was conducted wherein all the colorectal carcinomas, received in the Department of Pathology, over a period of 3 years, were reviewed. Neuroendocrine markers were done on 53 cases of moderately, poorly and undifferentiated adenocarcinomas. Based on the degree of immunoreactivity for these markers, tumours were divided into group 0, group 1, group 2, group 3 & group 4. Group 0 & 1 were categorized as neuroendocrine differentiation absent & group 2, 3 & 4 as present. Neuroendocrine differentiation was correlated with age, sex, grade, stage, diagnosis & survival. Follow up data of the cases was recorded. Results: Neuroendocrine differentiation was present in 18 cases (33.9%). The degree of immunoreactivity for neuroendocrine markers in present study were; group 0- 58%, 1- 7.5%, 2- 9%, 3- 13% & 4- 11%. The mean age of patients was 54 years with a slight male preponderance {M:F::1.6:1}. Most of the carcinomas with neuroendocrine differentiation belonged to Grade II (61%) & Stage II & III (83%). Neuroendocrine differentiation did not show any significant association with age, sex, location, histological type, grade, stage & survival. Conclusion: The above results indicate that the presence of neuroendocrine differentiation cannot be recommended as a prognostic marker in colorectal carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=84949201108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949201108&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2015/12800.6854

DO - 10.7860/JCDR/2015/12800.6854

M3 - Article

AN - SCOPUS:84949201108

VL - 9

SP - EC01-EC04

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 12

ER -